Small, but Detectable, Pancreatitis Risk With DPP-4 Inhibitors

A meta-analysis of DPP-4 inhibitor trials for type 2 diabetes finds small but significantly higher risk of acute pancreatitis but is "reassuring" on heart failure, renal function, and pancreatic cancer.